GenSight Biologics begins all-primary IPO in Paris
GenSight Biologics, a French biotechnology firm specialising in treatments for degenerative retinal diseases and central nervous system disorders, has opened the books for its all primary IPO on Euronext Paris.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts